A pan-Canadian prospective study of young women with breast cancer: the rationale and protocol design for the RUBY study

M.L. Quan MD MSc,^{*†‡} I.A. Olivotto MD,[†] N.N. Baxter MD PhD,^{§||} C.M. Friedenreich PhD,^{†‡‡}
K. Metcalfe RN PhD,^{**} E. Warner MD MSc,^{††} K. MacLennan MSc,^{‡‡} J.E. Stephen PhD,^{§§}
M.R. Akbari MD,^{||##} D. Howell RN PhD,[#] S. Narod MD,^{||##} and the RUBY site investigators

ABSTRACT

Introduction The understanding of the biology and epidemiology of, and the optimal therapeutic strategies for, breast cancer (BCa) in younger women is limited. We present the rationale, design, and initial recruitment of Reducing the Burden of Breast Cancer in Young Women (RUBY), a unique national prospective cohort study designed to examine the diagnosis, treatment, quality of life, and outcomes from the time of diagnosis for young women with BCa.

Methods Over a 4-year period at 33 sites across Canada, the RUBY study will use a local and virtual recruitment model to enrol 1200 women with BCa who are 40 years of age or younger at the time of diagnosis, before initiation of any treatment. At a minimum, comprehensive patient, tumour, and treatment data will be collected to evaluate recurrence and survival. Patients may opt to complete patient-reported questionnaires, to provide blood and tumour samples, and to be contacted for future research, forming the core dataset from which 4 subprojects evaluating genetics, lifestyle factors, fertility, and local management or delivery of care will be performed.

Summary The RUBY study will be the most comprehensive repository of data, biospecimens, and patient-reported outcomes ever collected with respect to young women with BCa from the time of diagnosis, enabling research unique to that population now and into the future. This research model could be used for other oncology settings in Canada.

Key Words Breast cancer, young-onset; prospective cohorts; pan-Canadian studies; knowledge translation; patient-reported outcomes; biorepositories

Curr Oncol. 2020 October 27(5):e516–e523

www.current-oncology.com

INTRODUCTION

In 2019, an estimated 26,900 Canadian women received a breast cancer (BCa) diagnosis and 5000 died from the disease¹. Women 40 years of age and younger account for approximately 5% of BCa cases and are more likely to be diagnosed with later-stage disease and to have biologically aggressive phenotypes, more recurrences, and greater mortality^{2–4}. Despite known differences in tumour phenotypes and outcomes in young compared with older women, the understanding of the biology and epidemiology of, and the optimal therapeutic strategies for, BCa in young women is limited. In addition, very little patient-reported experience and outcomes data have been generated, despite the unique challenges that patients face given their life stage

and age. Although cohort studies of young women with BCa such as the POSH⁵ and Harvard⁶ cohorts have been created, they did not recruit patients at the time of diagnosis, before treatment initiation, resulting in a knowledge gap for that critical period.

To address those issues and others, we designed the Reducing the Burden of Breast Cancer in Young Women (RUBY) study, a prospective cohort of young women recruited from a variety of practice settings across Canada at the time of their BCa diagnosis. In addition, we created a network of clinicians and researchers involved with delivery of BCa care, providing infrastructure for health systems research and knowledge translation of findings into practice.

This paper details the methods of the RUBY cohort study to illustrate the feasibility of oncology research in the

Correspondence to: May Lynn Quan, Foothills Medical Centre, Department of Surgery, 1403 29th Street NW, Calgary, Alberta T2N 2T9.
E-mail: maylynn.quan@ahs.ca ■ **DOI:** <https://doi.org/10.3747/co.27.6751>

real-world setting for a unique subpopulation of patients. The RUBY methods could be translatable to other diseases with similar research challenges.

METHODS

Study Design

The RUBY study is a prospective cohort study of patients newly diagnosed with BCa who are 40 years of age and younger. The goal is to recruit 1200 women from diverse Canadian settings, including non-academic sites. Enrolment in RUBY requires, at a minimum, consent to collect extensive chart review data to confirm details of diagnosis, treatment, and oncologic outcomes such as recurrence and death, the primary study outcomes. The second level of participation consists of online questionnaires, providing patient-reported outcomes measures, including factors previously not evaluable in this cohort (Table I). The third level of participation requires donation of biospecimens. Blood samples are taken before initiation of the 1st primary treatment and at years 1, 2, and 3, permitting further analysis of biomarkers, including hormones, inflammatory markers, micronutrient levels, and fertility measures over time. Germline mutation testing for common genes such as *BRCA1/2* and a panel of 23 genes (BROCAP, Table II) having known associations with BCa is done, as is whole-genome mapping. Tumour samples from surgical pathology specimens are processed into tissue microarrays for future molecular analysis. Finally, patients are asked for permission for future contact for research purposes. The patients are enrolled at the time of initial surgical consultation, after diagnosis, but before their first treatment (surgery or systemic therapy).

This core RUBY cohort data and biospecimen repository will serve to provide the infrastructure for 4 initial subprojects focusing on the role of genetics (KM), lifestyle and modifiable risk factors (CMF), fertility (EW), and local therapies or delivery of care (NNB), the details of which are described elsewhere—in addition to future studies.

Study Population

Women newly diagnosed with histologically-confirmed BCa are eligible to participate if they

- are diagnosed with invasive BCa, ductal carcinoma *in situ*, or malignant phyllodes tumour in Canada.
- are 18 or more years of age and have not yet reached their 41st birthday.
- are able to provide written informed consent and to complete questionnaires in English or French.

Recruitment

The recruitment sites (Table III) were selected to represent a variety of clinical practice settings. Sites with women from inner city, rural, Indigenous, and immigrant populations were cultivated, and provisions to support recruitment within those populations were enacted. The RUBY sites account for most of the BCa surgical treatment in their respective regions.

Each site identifies potentially eligible participants at initial referral to a surgeon once a diagnosis of malignancy

is known. Eligible patients are flagged so that clinic staff can introduce them to the study and seek verbal consent for direct contact by the RUBY study team. Two recruitment models are being used to accommodate local resources and capacity. The “local” (LRC) model is implemented at centres with available institutional research assistants or other personnel. The “virtual” (VRC) model is used at centres without available research resources, such that sites refer electronically, and the VRC located in Calgary contacts the patients directly by telephone or e-mail. The LRC or VRC is responsible for recruitment, consent, guidance for questionnaire completion, blood draws, and medical chart data abstraction. Eligibility or screening logs are maintained at each site. To optimize enrolment, e-mail reminder messages and study updates are sent at regular intervals.

Data Collection

Participants complete questionnaires online using the REDCap (Research Electronic Data Capture; REDCap Consortium, Vanderbilt University, Nashville, TN, U.S.A.) tool hosted at the Applied Health Research Centre (AHRC) at St. Michael's Hospital in Toronto, Ontario. Active follow-up for treatment and cancer outcomes with participant online questionnaires and chart abstraction will be conducted for up to 3 years. Passive follow-up will be conducted annually by regular vital status linkages and individual chart abstractions to identify dates and sites of any one or more of progression, recurrence, or new primary cancers. National and provincial administrative databases will be accessed through provincial patient health numbers to ascertain medical interventions, vital status, and if applicable, date and cause of death. Figure 1 depicts the flow through the study.

Patient Questionnaires

A link to access online questionnaires from the RUBY REDCap database is sent to participants by e-mail shortly after enrolment. Participants are asked to complete questionnaires at baseline (shortly after diagnosis, but before treatment), at 3 months, after initial active treatment (roughly 6–9 months), and annually for 3 years after enrolment. Table I summarizes the questionnaires requested for completion at each time point. The full set of instruments includes more than 2500 questions contained in more than 40 surveys.

Medical Record Abstraction

All diagnosis, staging, treatment, and follow-up care data are obtained through medical chart abstraction using a standardized abstraction tool and data dictionary. Either the LRC or the VRC conducts the chart abstraction at years 1 and 3. Relevant records are obtained from each institution's health records department or the participant's electronic medical record and are sent to the central coordinating centre at yearly intervals. All data are entered into the RUBY database by the LRCs or the VRC using the Web-based Medidata Rave application (3DS, Paris, France) housed at the AHRC in Toronto. Relevant medical variables, including all tumour and treatment data, are abstracted, as are oncologic outcomes including recurrence, progression, and death. We

TABLE I Questionnaires for participant completion

Questionnaire group	Study time point					
	Baseline	3 Months	Post treatment (6 or 9 months)	Post diagnosis		
				1 Year	2 Years	3 Years
Health questionnaires—module 1						
	Breast cancer diagnosis and treatment	Fertility	Breast surgery and reconstruction	Annual fertility	Annual fertility	Annual fertility
	Breast imaging and surgeries	Treatment plan		Annual genetics	Annual genetics	Annual genetics
	Menstrual and reproductive history					
	Birth control history					
	Medical history					
	Family history			Medical history follow-up	Medical history follow-up	Medical history follow-up
	Demographics					
Patient-reported outcomes—module 2						
	Breast-Q ¹²		Breast-Q	Breast-Q	Breast-Q	Breast-Q
	Cancer Behaviour Inventory ¹³ (CBI-B)		CBI-B	Cancer Survivor Self-Efficacy Scale	Cancer Survivor Self-Efficacy Scale	Cancer Survivor Self-Efficacy Scale
	General anxiety ¹⁴		General anxiety	General anxiety	General anxiety	General anxiety
	Feelings of depression ¹⁵		Feelings of depression	Feelings of depression	Feelings of depression	Feelings of depression
	PHQ-9 ¹⁶		PhQ-9	PhQ-9	PhQ-9	PhQ-9
	Trauma Checklist ¹⁷		Trauma Checklist	Trauma Checklist	Trauma Checklist	Trauma Checklist
	Personality Survey (IPIP) ¹⁸					
	Pittsburgh Sleep Quality Index ¹⁹		Pittsburgh Sleep Quality Index	Pittsburgh Sleep Quality Index	Pittsburgh Sleep Quality Index	Pittsburgh Sleep Quality Index
	Marital Adjustment ²⁰			Marital Adjustment	Marital Adjustment	Marital Adjustment
			Reproductive concerns after cancer	Reproductive concerns after cancer	Reproductive concerns after cancer	Reproductive concerns after cancer
			Use of psychological and CAM therapies	Use of psychological and CAM therapies	Use of psychological and CAM therapies	Use of psychological and CAM therapies
				Fear of cancer recurrence	Fear of cancer recurrence	Fear of cancer recurrence
			Illness Intrusiveness Rating scale	Illness Intrusiveness Rating scale	Illness Intrusiveness Rating scale	Illness Intrusiveness Rating scale
				Work situation	Work situation	Work situation
	MOS-Social Support (MOS-SS) ²¹		MOS-SS	MOS-SS	MOS-SS	MOS-SS
	Cancer Fatigue Scale (CFS) ²²		CFS	CFS	CFS	CFS
	Breast Cancer Prevention Trial Symptom Checklist (BCPT)		BCPT	BCPT	BCPT	BCPT
			Adherence-related measures	Adherence-related measures	Adherence-related measures	Adherence-related measures
	Beliefs about medicines		Beliefs about medicines	Beliefs about medicines	Beliefs about medicines	Beliefs about medicines

TABLE I Continued

Questionnaire group	Study time point					
	Baseline	3 Months	Post treatment (6 or 9 months)	Post diagnosis		
				1 Year	2 Years	3 Years
	Side-effect expectations		Side-effect expectations	Side-effect expectations		
	Brief Illness Perception Questionnaires (BIPQ) ²³		BIPQ	BIPQ	BIPQ	BIPQ
				Decision Regret Scale	Decision Regret Scale	Decision Regret Scale
<i>Lifestyle—module 3</i>						
	Lifestyle					
	Physical Activity and Sedentary Behaviour Questionnaire ¹¹			Physical Activity and Sedentary Behaviour Questionnaire		Physical Activity and Sedentary Behaviour Questionnaire
	Food Frequency Questionnaire ¹⁰			Food Frequency Questionnaire		Food Frequency Questionnaire
<i>Total time commitment</i>						
	2–2.5 Hours	10 Minutes	45–60 Minutes	1.5–2 Hours	45–60 Minutes	1.5–2 Hours

TABLE II The known breast (BCa) and ovarian cancer (OCa) predisposing genes and their characteristics by risk category

Gene	Chromosome	Gene	Chromosome	Gene	Chromosome	Gene	Chromosome
<i>ATM</i>	11	<i>EPCAM</i>	2	<i>NBN</i>	8	<i>RAD51D</i>	17
<i>BARD1</i>	2	<i>FAM175A</i>	4	<i>PALB2</i>	16	<i>STK11</i>	19
<i>BRCA1</i>	17	<i>MLH1</i>	3	<i>PPM1D</i>	17	<i>TP53</i>	17
<i>BRCA2</i>	13	<i>MRE11A</i>	11	<i>PMS2</i>	7	<i>XRCC2</i>	7
<i>BRIP1</i>	17	<i>MSH2</i>	2	<i>PTEN</i>	10		
<i>CDH1</i>	16	<i>MSH6</i>	2	<i>RAD50</i>	5		
<i>CHEK2</i>	22	<i>MUTYH</i>	1	<i>RAD51C</i>	17		
Characteristic		High risk		Moderate risk		Newer	
Symbol		<i>BRCA1, BRCA2, CDH1, EPCAM, PMS2, PTEN, MLH1, MSH2, MSH6, STK11, TP53</i>		<i>ATM, CHEK2, PALB2</i>		<i>BARD1, BRIP1, FAM175A (ABRAXAS), MRE11A, MUTYH, NBN, RECQL, RAD50, RAD51C, RAD51D, XRCC2</i>	
Associated risk for BCa or OCa		Significantly increased risk (usually at least 4x, often more)		Moderately increased risk (approximately 2–4x)		Exact lifetime risk not yet known	
Risk for other cancers?		Can increase the risk		Can increase the risk		Can increase the risk	
Well studied?		Yes		Yes		Not as well	
Guidelines for screening and prevention?		Defined guidelines available		No defined guidelines yet available		No defined guidelines yet available	

previously used established data collection methods to retrospectively collect those data elements at a population level in Ontario, Alberta, British Columbia, and Quebec^{7–9}.

Blood Sample Collection

All participants consenting to provide blood samples are provided requisitions and have their blood drawn at designated laboratories. Local clinical labs were selected

at each site to minimize extra visits for patients; they include hospital-based labs, research-nurse draws during clinical encounters, and provincial or group lab contracts (LifeLabs, Ontario; Alberta Precision Laboratories, Alberta). Each laboratory collects and processes blood samples according to the RUBY blood protocol (Figure 2). Samples are shipped to the central biobank at Women's College Hospital semi-annually.

TABLE III Recruitment sites in RUBY active as of January 2019 (exceptions denoted with an asterisk)

1	BC Cancer, Vancouver, BC*
2	Calgary Breast Health Program, Calgary, AB
3	Cancer Centre of Southeastern Ontario, Kingston, ON
4	Centre des maladies du sein Deschênes-Fabia, Quebec City, QC
5	CHUM Breast Cancer Clinic, Montreal, QC
6	Edmonton Comprehensive Breast Care Program, Edmonton, AB
7	Guelph General Hospital, Guelph, ON
8	IWK Health Centre, Halifax, NS
9	Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC
10	Juravinski Cancer Centre, Hamilton, ON
11	Irene and Leslie Dubé Centre of Care, Saskatoon, SK
12	Lethbridge Breast Health Program, Lethbridge, AB
13	London Breast Clinic, London, ON
14	Hôpital Maisonneuve-Rosemont, Montreal, QC
15	McGill University Health Centre, Montreal, QC
16	Nanaimo Regional General Hospital, Nanaimo, BC
17	Dr. H. Bliss Murphy Cancer Centre, St John's, NL
18	North York General Hospital Breast Diagnostic Clinic, Toronto, ON
19	Princess Margaret Hospital, Toronto, ON
20	Providence Breast Centre, Vancouver, BC
21	Sault Area Hospital, Sault Ste. Marie, ON
22	Sindi Ahluwalia Hawkins Centre for the Southern Interior, Kelowna, BC
23	Simcoe Muskoka Regional Cancer Centre, Barrie, ON
24	St. Michael's Hospital, Toronto, ON
25	Louise Temerty Breast Cancer Centre, Toronto, ON
26	Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON
27	Trillium Health Partners, Mississauga, ON
28	University of British Columbia, Victoria, BC
29	William Osler Health System, Brampton, ON
30	Winnipeg Regional Health Authority, Breast Health Centre, Winnipeg, MB
31	Women's Breast Health Centre, Ottawa, ON
32	Women's College Hospital, Toronto, ON
33	Yukon Surgical Clinic, Whitehorse, YT

Tumour Specimens

Participants who consent to release their formalin-fixed, paraffin-embedded tumour blocks for future research have their tissue blocks sent to Women's College Hospital in Toronto for processing. Tissue microarrays are made after

FIGURE 1 Patient flow through the study. **FIGURE 2** Process of collection and banking of serum, plasma, red blood cells, and buffy coats according to the standardized RUBY cohort study procedures. RBCs = red blood cells; AMH = anti-Müllerian hormone.

DNA and RNA are extracted from the tumour blocks. Sites with pathology capacity can also extract and create tissue microarrays directly for the RUBY biobank; the microarrays are then linked to clinical and outcomes data.

Data Management

Overall data management is conducted by the project team in Calgary using a central tracking database to monitor participant flow through the study and a unique RUBY identifier to link medical-record, patient-reported, and biospecimen data. The AHRC is the coordinating and data management centre responsible for receiving patient-reported and chart data. It has a dedicated project manager who liaises with the RUBY VRC, LRCs, and project team in Calgary.

Sample Size

We estimated participant recruitment based on an annual projection of 1260 new cases of BCa in women 40 years of age and younger to be recruited between 2015 and 2020. We estimate that our surgeon collaborators care for approximately 80% of new patients with BCa in Canada. We anticipate enrolling 30%–40% of those patients, (approximately 300 participants per year over 4 years) for a total enrolment of 1200 participants. At the time of writing we had anticipated recruitment to be completed by March 2020. That date has been affected by the COVID-19 pandemic.

Patient and Public Involvement

A research retreat of RUBY site leads, patient and family representatives, and community and patient advocates from Canadian agencies, including the Canadian Breast Cancer Network, was held in March 2017. A priority-setting partnership, inviting patients, family members, and caregivers to identify research priorities, was initiated in October 2019, with completion planned for the fall of 2020.

Ethics

Ethics approval was obtained from each site's review boards and has been renewed as required. Separate ethics approval for each subproject has been obtained from the subproject lead's institution.

RESULTS AT APRIL 2020

Recruitment Processes

At April 2020, 33 recruitment sites had been activated (Table III). Each RUBY recruitment site has a surgeon lead working with 1–10 other surgeons. Most centres ($n = 22$) are using LRCs; the others ($n = 11$) are using the VRC. That model permits recruitment at sites generally not accessible to traditional academic institution–based researchers, thus broadening the diversity of the cohort.

Participants

Recruitment started in July 2015. At 29 April 2020, 1161 participants had been recruited from 33 sites (Figure 3), for an average of 20 participants per month. Although it was projected that the planned sample size would be complete by March 2020 (Figure 4), the COVID-19 pandemic has affected recruitment timelines. At the time of writing, resumption of clinical services remains uncertain. The trial will continue to recruit after a 2-month suspension, but blood draws are on hold, and some sites are unable to provide support because of redeployment. We now estimate achieving our target by the end of 2020.

Recruitment logs of eligible patients identified at each RUBY site were maintained from July 2015 until June 2017. During that time, 78.6% of eligible women were recruited. Themes reported as reasons for non-enrolment included patients being too overwhelmed, having no capacity to commit to the study, or not responding to repeated contact attempts after initially agreeing to be contacted. Calls with each RUBY surgeon principal investigator and the LRCs were held to troubleshoot location-specific barriers and to collaborate on potential solutions. In addition, monthly LRC

FIGURE 3 Geographic distribution of RUBY study participants based on province or territory of origin.

FIGURE 4 Recruitment progress (sample size plotted with initial projections). The planned sample size of 1200 participants had been anticipated to be achieved in March 2020.

and VRC teleconferences are held to provide important study updates and support from the central team, to obtain feedback from sites, and to foster engagement within the RUBY LRC community. To foster the RUBY network brand, quarterly RUBY newsletters are distributed digitally, highlighting RUBY achievements, recruitment sites, and personnel.

RUBY Data Collection

At April 2020, 81.4% of the 1161 participants enrolled had agreed to all components of the study. Almost all agreed to provide biospecimens; 1080 of the 1161 (93.0%) provided a baseline blood sample, and 1131 (97.4%) gave consent for access to their formalin-fixed, paraffin-embedded tumour blocks. Table IV shows the proportion of participation in each study component. At April 2020, 89% of the participants had responded to one or more of the questionnaires.

The consent for chart review, questionnaires, and blood samples permitted the objectives of 3 of the 4

TABLE IV Study components completed by participants

Component	Participants completing			Sample size	Percentage completing
	English	French	Total		
Questionnaires	980	150	1130	1161	97.3
Blood samples	935	145	1080	1161	93.0
FFPE samples	985	146	1131	1160 ^a	97.5
Future contact	870	139	1009	1161	86.9

^a When providing consent, 1 participant did not provide a response to this option.
FFPE = formalin-fixed, paraffin-embedded.

subprojects to be embedded within the core RUBY processes. The 4th subproject evaluating the association of germline mutations is consented separately. Participants in RUBY who consent for future research contact and who provide a blood sample at baseline are contacted 3 months after their initial surgical consultation. A specific consent outlining the risks and benefits associated with gene testing is obtained. Because of batched shipping of blood samples, participants and surgeons are informed that results are not timely for clinical care and should not replace standard clinical testing or usual practice. At April 2020, 858 patients had been contacted, and 580 (68%) had consented to gene testing.

Primary Tumour and Treatment Data

At 29 April 2020, medical chart data for 610 patients had been entered. A revision of the Rave platform was performed in August 2019 in response to LRC feedback. Data validation for each patient chart is being performed by the core research team to ensure accuracy and to decrease missing data.

SIGNIFICANCE AND IMPACT

To date, we have successfully implemented—for an important and understudied oncology population—a national, comprehensive, and complex recruitment infrastructure that has achieved 97% of planned enrolment, with high levels of participation across all optional study domains, including patient-reported questionnaires, blood and tumour specimens, and consent for future contact. We have demonstrated the feasibility of recruiting patients outside traditional clinical trial environments in surgical offices, clinics, and centres, allowing for collection of data that starts at the time of diagnosis, which previously represented a gap in knowledge for patients with young-onset BCa.

Moreover, the creation of the RUBY network—consisting of site principal investigators who will act as knowledge translation vectors—will directly affect patient care and inform regional policies and programming for clinical care. To date, the RUBY network of surgeons has formally contributed to national BCa surgery standards¹⁰ and consensus statements about contralateral prophylactic mastectomy¹¹, and has had numerous informal communications and sharing of practices and experience.

The RUBY study will be the most comprehensive repository of data, biospecimens, and patient-reported outcomes ever collected for young women with BCa, which will enable

productive research unique to this population now and in the future. This research model could be used for other oncology settings in Canada.

ACKNOWLEDGMENTS

This study is jointly funded by the Canadian Institutes of Health Research and the Canadian Breast Cancer Foundation–National (now Canadian Cancer Society–Research) 5-year grant competition for research about young women with BCa. Special thanks to Susan Isherwood PhD and Agota Ferenc MSc for project and data management in the creation of the cohort and manuscript.

CONFLICT OF INTEREST DISCLOSURES

We have read and understood *Current Oncology's* policy on disclosing conflicts of interest, and we declare that we have none.

AUTHOR AFFILIATIONS

*Department of Surgery, Cumming School of Medicine, †Department of Oncology, Cumming School of Medicine, and ‡Department of Community Health Sciences, University of Calgary, Calgary, AB; §Department of Surgery, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and ||Women's College Hospital, University of Toronto, Toronto, ON; #Department of Cancer Epidemiology and Prevention Research, CancerControl Alberta, Alberta Health Services, Calgary, AB; **Lawrence S. Bloomberg Faculty of Nursing, ††Division of Medical Oncology, Sunnybrook Odette Cancer Centre, and ‡‡Applied Health Research Centre (AHRC), Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, Toronto, ON; §§Clinical Neurosciences Program, Alberta Health Services, Calgary, AB; ##Dalla Lana School of Public Health, University of Toronto, Toronto, ON.

REFERENCES

1. Canadian Cancer Statistics Advisory Committee. *Canadian Cancer Statistics 2019*. Toronto, ON: Canadian Cancer Society; 2019.
2. Voogd AC, Nielsen M, Peterse JL, *et al.* Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. *J Clin Oncol* 2001;19:1688–97.
3. Rubino C, Arriagada R, Delaloge S, Le MG. Relation of risk of contralateral breast cancer to the interval since the first primary tumour. *Br J Cancer* 2010;102:213–19.
4. Narod SA. Breast cancer in young women. *Nat Rev Clin Oncol* 2012;9:460–70.
5. Copson E, Eccles B, Maishman T, *et al.* Prospective observational study of breast cancer treatment outcomes for U.K. women aged 18–40 years at diagnosis: the POSH study. *J Natl Cancer Inst* 2013;105:978–88.
6. Rosenberg SM, Sepucha K, Ruddy KJ, *et al.* Local therapy decision-making and contralateral prophylactic mastectomy

- in young women with early-stage breast cancer. *Ann Surg Oncol* 2015;22:3809–15.
7. Quan ML, Osman F, McCready D, Fernandes K, Sutradhar R, Paszat L. Postmastectomy radiation and recurrence patterns in breast cancer patients younger than age 35 years: a population-based cohort. *Ann Surg Oncol* 2014;21:395–400.
 8. Bérubé S, Provencher L, Robert J, *et al.* Quantitative exploration of possible reasons for the recent improvement in breast cancer survival. *Breast Cancer Res Treat* 2007;106:419–31.
 9. Cao JQ, Truong PT, Olivotto IA, *et al.* Should women younger than 40 years of age with invasive breast cancer have a mastectomy? 15-Year outcomes in a population-based cohort. *Int J Radiat Oncol Biol Phys* 2014;90:509–17.
 10. Canadian Partnership Against Cancer (CPAC). *Pan-Canadian Standards: Breast Cancer Surgery*. Toronto, ON: CPAC; 2019.
 11. Wright FC, Look Hong NJ, Quan ML, *et al.* Indications for contralateral prophylactic mastectomy: a consensus statement using modified Delphi methodology. *Ann Surg* 2018;267:271–9.